The read at a glance
Computed from the FY2025 annual filing. Full history and the components behind each score are in the app.
- Distress risk · Altman Z-Score -69.17 — distress zone — historically elevated failure riskWatch
Where the revenue comes from
Fiscal 2025, as Marker Therapeutics, Inc. reports it. History and quarterly detail are in the app.
- Grant$3.5M
- Cancer Prevention And Research Institute Of Texas Acute Myeloid Leukemia$900K
- National Institutes Of Health Small Business Innovation Research For Lymphoma Grant$665K
- Cprit Pancreatic Grant$574K
- National Institutes Of Health Small Business Innovation Research$472K
Leadership changes
From Marker Therapeutics, Inc.'s own filings, the day they're filed.
- Kathryn Penkus Corzo · Directors · appointmenteff. 2025-11-01
- Eliot M. Lurier · Chief Financial Officer · appointmenteff. 2023-06-30
- Eliot M. Lurier · Chief Financial Officer · appointment
Latest filings
- 10-Q · Quarterly report2026-08-14
- 10-Q · Quarterly report2026-05-15
- 8-K · Company announcement2026-05-04
- DEF 14A · Annual proxy (pay & governance)2026-03-20
- 8-K · Company announcement2026-03-19
In the full recordFree for 14 days
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Marker Therapeutics, Inc., every answer cited to the official filings🔒
- The Intelligence Brief — added when Marker Therapeutics, Inc.'s brief passes our SEC-figure check🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.